(ELDN) – Press Releases
-
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
-
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
-
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
-
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook
-
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
-
Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference
-
Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results
-
Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference
-
Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation
-
Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer
-
Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting
-
Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors
-
Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human
-
Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
-
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
-
Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates
-
Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation
-
Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation
-
Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results
-
Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference
-
Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results
-
Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
-
Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
-
Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
-
Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology
-
Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology
-
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results
-
Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results
-
Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023
-
Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023
-
Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023
-
Eledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023
-
Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
-
Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
-
Eledon Pharmaceuticals Provides Business and Pipeline Updates
-
Eledon Pharmaceuticals Provides Business and Pipeline Updates
-
eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies
-
eGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies
-
C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System
-
Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results
-
Eledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results
-
Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
-
Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022
-
Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
-
Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS
-
Eledon Pharmaceuticals to Participate in Two Upcoming Conferences
-
Eledon Pharmaceuticals to Participate in Two Upcoming Conferences
-
Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
Back to ELDN Stock Lookup